Author information from the last article
Articles by Kjell-Morten Myhr
New centres to carry out more clinical trials in Norway
- Inger Marie Skoie,
- Jan Gunnar Skogås,
- Thomas Langø,
- Kjell-Morten Myhr,
- Peder Langeland Myhre,
- Rasmus Goll,
- Signe Øien Fretland,
- Åslaug Helland
20.01.2023:
Six NorTrials centres for clinical research have been established at the university hospitals. Their objective is to increase the number of clinical trials and improve patient treatment. We know that patients treated in institutions where clinical trials are undertaken have better outcomes (1). This...
Breastfeeding and treatment for multiple sclerosis
- Øivind Torkildsen,
- Brit Ellen Rød,
- Lars Bø,
- Stig Wergeland,
- Trygve Holmøy,
- Kjell-Morten Myhr
24.10.2022:
Monoclonal antibody therapy is effective for multiple sclerosis, and only small amounts of antibodies are transferred to breast milk. Even though the approved product descriptions advise against breastfeeding during medicinal treatment, several of the most effective MS drugs are compatible with...
Disease-modifying therapy for multiple sclerosis
- Trygve Holmøy,
- Gro Owren Nygaard,
- Kjell-Morten Myhr,
- Lars Bø
10.05.2021:
High-efficacy therapy from the time of diagnosis substantially improves the prognosis for multiple sclerosis. The national guidelines on MS nevertheless recommend less effective therapy for many patients, and must be updated in pace with medical advances. We consider in the following how multiple...
Progressive multifocal leukoencephalopathy
- Karl Bjørnar Alstadhaug,
- Kjell-Morten Myhr,
- Christine Hanssen Rinaldo
12.12.2017:
Progressive multifocal leukoencephalopathy is a rare, opportunistic infection of the central nervous system caused by the John Cunningham virus (JCV). There is no effective antiviral treatment available, and restoring immunocompetence is essential for survival. If this occurs too quickly, however...